Related Experiment Videos
Photofrin II localization in rat cecum.
D J Bjorkman1, E J Brigham, B J Peterson
1Division of Gastroenterology, Utah Laser Institute, University of Utah School of Medicine, Salt Lake City 84132.
Lasers in Surgery and Medicine
|January 1, 1989
Summary
Photodynamic agents like Photofrin II show potential for colon cancer diagnosis and treatment. However, increased fluorescence in the cecum may impact treatment efficacy for cecal tumors.
Area of Science:
- Biomedical optics
- Cancer research
- Photodynamic therapy
Background:
- Photodynamic agents are being explored for colon cancer diagnosis and treatment.
- High tumor-to-background fluorescence ratios are crucial for photosensitizer efficacy.
- Understanding photosensitizer distribution in normal tissues is essential.
Purpose of the Study:
- To evaluate normal colonic background fluorescence.
- To assess hematoporphyrin accumulation in the colon after Photofrin II administration.
- To determine the impact of cecal accumulation on photodynamic therapy efficacy.
Main Methods:
- Intravenous injection of Photofrin II (5 mg/kg) into 31 rats.
- Measurement of mucosal fluorescence and porphyrin content in the colon.
- Assessment of fluorescence 24 hours post-injection.
Main Results:
- Increased mucosal fluorescence and porphyrin content were observed in the cecum.
- A 24-hour time point revealed significant accumulation of Photofrin II in the cecum.
- The findings suggest potential interference with cecal tumor localization and treatment.
Conclusions:
- Cecal accumulation of Photofrin II may compromise its effectiveness for cecal tumors.
- Further research is needed to understand the mechanism and clinical implications of this finding.
- Optimizing photosensitizer distribution is key for successful photodynamic therapy in the colon.